Connect to share and comment

Agenus genital herpes vaccine succeeds in mid-stage trial

(Reuters) - Agenus Inc said a mid-stage trial of its experimental genital herpes vaccine reduced the rate at which patients' were shedding the virus. The 15 percent reduction in viral shedding in patients receiving the vaccine compared to those on a placebo, who showed no reduction. The mid-stage trial had 80 patients with a history of 1-9 herpes recurrences within the prior 12 months. Of them, 70 received the vaccine, HerpV, and 10 received placebo.

Alberta spends more on sexual transmitted infection awareness, cases increase

EDMONTON - The Alberta government says the rate for some sexually transmitted infections continues to increase despite a $2 million public awareness campaign in 2011. Alberta Health says it is spending $1.6 million this fall on a new round of media ads aimed at young adults that promotes safer sex. The government says the infection rates for gonorrhea and chlamydia are up. The campaign includes TV, online and cinema ads as well as posters in bars.

Reuters Health News Summary

Following is a summary of current health news briefs. New boss of meningitis-linked firm is poor choice: U.S. official BOSTON (Reuters) - The person hired to run the bankrupt pharmacy linked to a deadly U.S. meningitis outbreak is "hopelessly conflicted" and should be removed from the job, a U.S. Justice Department official said on Tuesday. William Harrington, the U.S. Trustee for Region One, argued that New England Compounding Center's board should not be able to hand-pick its chief restructuring officer.

Treatment-resistant gonorrhea threat rises in North America

* Canadian scientists document several cases of treatment failure * CDC official says "it's only a matter of time" to reach U.S. By Julie Steenhuysen CHICAGO, Jan 8 (Reuters) - The only remaining oral antibiotic used for gonorrhea failed to cure the infection in nearly 7 percent of patients treated at a clinic in Toronto, Canadian researchers said on Monday in the first published study of treatment-resistant gonorrhea in North America.
Syndicate content